Skip to main content
Autobound logo

What Bio-Techne's latest 10-Q says: 5 signals

Bio-Techne filed its latest 10-Q with the SEC on May 6, 2026. It discusses acquisition announced, capacity constraint and capex increase.

Public (TECH)Biotechnology Research1,001 to 5,000 employeesbio-techne.comLinkedIn

Filed
May 6, 2026
Filings
2
Signals
13

10-Q · latest 10

What Bio-Techne's 10-Q filings say

  1. 10-Q

    Filed · 5 signals

    SEC EDGAR

  2. 10-Q

    Filed · 8 signals

    SEC EDGAR

Showing 10 of 13 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Bio-Techne earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Prioritizing productivity and disciplined cost management amid revenue headwindsThe company is actively managing costs and streamlining operations to protect profitability amidst market softness and a temporary slowdown in a key business segment. This focus on efficiency creates opportunities for vendors offering cost-saving or productivity-enhancing solutions.
Facing significant near-term revenue headwind in key cell therapy businessCustomer success with FDA Fast Track designations has created a temporary but significant "air pocket" in reagent demand, impacting overall growth by up to 400 basis points in Q2. This volatility creates pressure to find growth in other areas and manage through the downturn.
Exceeding profitability via disciplined cost management and productivity focus.Leadership is driving significant operating margin expansion through a "deliberate focus on productivity and cost management." This indicates a high receptivity to solutions that offer efficiency, automation, and cost savings to protect the bottom line amidst market volatility.
Committing budget to strategic growth initiatives despite market headwinds.Despite a focus on cost control, the company is explicitly making "targeted investments in strategic growth initiatives." This signals that dedicated budget is available for projects and vendors that align with their core growth pillars, even in a challenging revenue environment.
Launching multiple new products, signaling investment in commercialization.The company is launching several new products, including the ProximityScope assay, an ultrasensitive Ella cartridge, and the AmplideX PML-RARA kit. These launches require investment in marketing, sales enablement, and supply chain, creating opportunities for supporting vendors.
Maintaining stable R&D spending at 8.2% of revenue for innovation.The company is sustaining its investment in innovation, with R&D expense stable at 8.2% of revenue. This budget is funding advancements across key platforms to enhance functionality and broaden applications, signaling a commitment to technology development and the tools required to support it.

Signal API · MCP

Track Bio-Techne with the Signal API

One POST /v1/companies/enrich call with bio-techne.com returns Bio-Techne 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bio-techne.com","signal_types":["sec-10q"],"limit":20}'

Same industry

10-Q at related companies

Questions about Bio-Techne 10-Q

When did Bio-Techne file its latest 10-Q?
Bio-Techne filed its latest 10-Q on May 6, 2026. The one before it was filed on Feb 4, 2026.
What did Bio-Techne disclose in its latest 10-Q?
From the filing dated May 6, 2026: Bio-Techne forecasts ~$1B payment to acquire remaining 80.1% of Wilson Wolf
What did Bio-Techne say on its recent earnings calls?
Q1 FY2026: Prioritizing productivity and disciplined cost management amid revenue headwinds (dated Nov 5, 2025).
Where can I read Bio-Techne's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →